FASLODEX
Main information
- Trade name:
- FASLODEX 1 U. INJ
- Active ingredient:
- FULVESTRANT
- Available from:
- Astrazeneca
- Dosage:
- 250MG (IN 5ML. SOL. ETHANOL 96%)
- Pharmaceutical form:
- INJ
- Composition:
- 1 U.
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
9-4-2018
Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 19, Authorised
Europe - EMA - European Medicines Agency
2-2-2018
Human medicines European public assessment report (EPAR): Fulvestrant Mylan, fulvestrant, Revision: 0, Authorised
Europe - EMA - European Medicines Agency
26-1-2018
Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 18, Authorised
Europe - EMA - European Medicines Agency
10-11-2017
Pending EC decision: Fulvestrant Mylan, fulvestrant, Opinion date: 09-Nov-2017
Europe - EMA - European Medicines Agency
13-10-2017
Pending EC decision: Faslodex, fulvestrant, Opinion date: 12-Oct-2017
Europe - EMA - European Medicines Agency
2-10-2017
Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 17, Authorised
Europe - EMA - European Medicines Agency
22-6-2017
Pending EC decision: Faslodex, fulvestrant, Opinion date: 22-Jun-2017
Europe - EMA - European Medicines Agency
18-10-2016
FASLODEX (fulvestrant) - Risk of Unnecessary Therapy Modification due to Falsely Elevated Estradiol Levels
MedEffect Canada
23-3-2018
Faslodex (AstraZeneca AB)
Faslodex (Active substance: Fulvestrant) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1898 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/540/T/63
Europe -DG Health and Food Safety
10-1-2018
Fulvestrant Mylan (Mylan S.A.S.)
Fulvestrant Mylan (Active substance: fulvestrant) - New authorisation - Commission Decision (2018)133 of Wed, 10 Jan 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4649
Europe -DG Health and Food Safety
28-8-2017
![FASLODEX (Fulvestrant) Injection [AstraZeneca Pharmaceuticals LP]](/web/assets/global/img/flags/us.png)
FASLODEX (Fulvestrant) Injection [AstraZeneca Pharmaceuticals LP]
Updated Date: Aug 28, 2017 EST
US - DailyMed
24-5-2017
Faslodex (AstraZeneca UK Limited)
Faslodex (Active substance: Fulvestrant) - Centralised - Yearly update - Commission Decision (2017)3642 of Wed, 24 May 2017
Europe -DG Health and Food Safety